THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call
Detailed price information for Lexicon Pharmaceutcl (LXRX-Q) from The Globe and Mail including charting and trades.
Lexicon Pharmaceuticals (NASDAQ:LXRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time
The analyst fair value estimate for Lexicon Pharmaceuticals has shifted from US$3.77 to US$4.55 per share, reflecting a higher modeled upside in the latest work. Recent Street commentary links this move to growing focus on sotagliflozin and the fully enrolled Phase 3 SONATA HCM trial, which has a defined data readout in 1Q27. As you read on, you will see how these factors shape the evolving Lexicon Pharmaceuticals story and what to watch as the narrative develops. Stay updated as the Fair...
Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. Click for this updated look at LXRX.
An analyst at a prominent research firm initiated coverage of the
Cantor starts Lexicon at overweight with an $8 price target. Read more here.
Lexicon Pharmaceuticals (LXRX) shares rose 7.5% in Monday trading after Cantor Fitzgerald initiated
Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).
Lexicon Pharmaceuticals (NASDAQ:LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027. Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Chief Executiv
THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking place in New York, NY: Citi 2026 Biopharma Back to School Conference September 9, 2026, 11:20–11:55 AM (Eastern Time) 2026 Cantor Global Healthcare ConferenceSeptember 10, 2026, 3:20–3:50 PM (Eastern Time) H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 14, 2026, 9:00–9:30 AM (Eas
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart FailureTHE WOODLANDS, Texas, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The data, which were presented yesterday at ESC Congres
Detailed price information for Maxcyte Inc (MXCT-Q) from The Globe and Mail including charting and trades.
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has earned a third $10 million milestone payment in 2026 from Novo Nordisk A/S foll
Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.
This is the newest page. Registered accounts read further back.